Medtronic Stock Price, News & Analysis

Medtronic (NYSE:MDT) has integrated the Hugo robotic-assisted surgery system at Hospital Clinico de la Red de Salud UC CHRISTUS in Santiago, Chile, enhancing access to minimally invasive procedures. This partnership marks a significant step in Medtronic's Partners in Possibility Program. The system aims to address cost barriers and improve surgical outcomes, as currently, only 3% of surgeries utilize robotic assistance globally. Additionally, a new Surgical Robotics Experience Center has opened in Santiago for clinician training. The Hugo RAS system is not yet cleared in the U.S. or Europe.

Medtronic plc (NYSE:MDT) announced an economic model based on the PRODIGY trial, demonstrating that continuous pulse oximetry and capnography monitoring can save over $500,000 annually for hospitals. This model predicts a reduction in respiratory depression by 20%, leading to a decrease of 103 patient days per year in a median-sized U.S. hospital. The findings emphasize the heightened safety and cost-effectiveness of continuous monitoring for patients receiving opioids compared to intermittent methods, supporting the company's commitment to improving patient outcomes.

Medtronic (NYSE:MDT) has launched the DEFINE AFib study, the first app-based research initiative aimed at understanding atrial fibrillation (AF) burdens and their effects on patient outcomes. Enrolling around 5,000 patients, the study utilizes data from the LINQ insertable cardiac monitors and the Medtronic Discovery App™. This remote study will enhance AF management through a machine learning approach, leveraging both device data and patient-reported information. Conducted with leading medical centers, it aims to personalize AF management strategies.

Medtronic plc (NYSE:MDT) presented significant clinical data at the American Diabetes Association's 81st Scientific Sessions, showcasing the InPen smart insulin pen and an extended-wear infusion set. Results indicated a 2.3% and 5% increase in Time in Range for users with glycemic management indicators over 8% and 9.5%, respectively, with no rise in hypoglycemia. Additionally, a study on the seven-day infusion set demonstrated sustained insulin delivery without severe adverse events. Both innovations aim to enhance diabetes management and patient experience.

Medtronic plc (NYSE: MDT) announced its participation in the ADA 81st Scientific Sessions from June 25-29, 2021. The company will present seven data presentations, including insights on its InPen smart insulin pen and Extended Infusion Set. Key studies include the impact of InPen on glycemic outcomes and results from the EWIS pivotal trial. Additionally, Medtronic will host a product theater and offer on-demand learning sessions, showcasing advancements in diabetes management technology aimed at improving patient care and glucose control.

On June 19, 2021, Medtronic (NYSE:MDT) successfully performed the first patient procedure using its Hugo™ robotic-assisted surgery (RAS) system at Clínica Santa María in Santiago, Chile. This milestone initiates the global patient registry for the Hugo RAS system, aimed at collecting clinical data for regulatory submissions worldwide. The system promises to enhance surgical precision while minimizing invasiveness, ultimately leading to better patient outcomes. However, the Hugo RAS system is not yet approved in the U.S. or Europe, with regulatory timelines yet to be determined.

Medtronic plc (NYSE: MDT) announced FDA expanded approval for its Arctic Front™ Family of Cardiac Cryoablation Catheters as an initial rhythm control strategy for recurrent symptomatic paroxysmal atrial fibrillation. This is the first approval allowing cryoablation before antiarrhythmic drug therapy failure. Results from the STOP AF First study showed cryoablation significantly outperforms drug therapy in preventing arrhythmia recurrence. Nearly 60 million people are affected by atrial fibrillation globally, with this new option providing a safer, effective alternative to traditional treatments.

Medtronic plc (NYSE: MDT) has received FDA approval for its Vanta™ neurostimulator, a recharge-free implantable device with a lifespan of up to 11 years, nearly doubling that of competitive devices. It features AdaptiveStim™ technology, which adjusts to patient movement, offering personalized pain relief. The device is designed for broad MRI compatibility, crucial for the 82% of spinal cord stimulation patients requiring MRI scans within five years. The Vanta is 20% smaller than its predecessor and includes data insights via Snapshot™ reporting.

Medtronic plc (NYSE:MDT) announced the STROKE AF trial results showing the Reveal LINQ™ Insertable Cardiac Monitor (ICM) significantly outperformed standard care in detecting atrial fibrillation (AF) in stroke patients. The study involved 496 patients, revealing AF detection rates of 12.1% in the ICM group versus 1.8% in standard care. The findings underscore the importance of long-term monitoring for stroke prevention, as 78% of AF patients could have been missed with traditional monitoring. The results, published in JAMA, highlight the potential for ICMs to transform secondary stroke prevention practices.